Nanobiotix S.A.
NBTX
$3.39
$0.24117.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -138.66% | -20.08% | -- | -- | -- |
| Total Other Revenue | -28.14% | -18.13% | -8.27% | 10.23% | 34.32% |
| Total Revenue | -119.90% | -19.50% | 547.32% | 611.18% | 691.49% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -119.90% | -19.50% | 547.32% | 611.18% | 691.49% |
| SG&A Expenses | -6.88% | 4.70% | 18.62% | 23.85% | 26.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.05% | 12.29% | 25.72% | 25.69% | 22.63% |
| Operating Income | -182.08% | -32.03% | 50.12% | 47.17% | 45.86% |
| Income Before Tax | -72.05% | -5.43% | 41.58% | 34.39% | 28.63% |
| Income Tax Expenses | -15.94% | 183.16% | 3,822.22% | 2,246.59% | 1,125.47% |
| Earnings from Continuing Operations | -71.79% | -5.67% | 41.13% | 34.06% | 28.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.79% | -5.67% | 41.13% | 34.06% | 28.43% |
| EBIT | -182.08% | -32.03% | 50.12% | 47.17% | 45.86% |
| EBITDA | -191.86% | -36.99% | 49.49% | 46.96% | 46.10% |
| EPS Basic | -30.94% | 18.95% | 53.14% | 41.40% | 30.84% |
| Normalized Basic EPS | -60.48% | 13.56% | 61.38% | 46.54% | 32.34% |
| EPS Diluted | -30.40% | 18.82% | 52.73% | 41.07% | 30.63% |
| Normalized Diluted EPS | -60.48% | 13.56% | 61.38% | 46.54% | 32.34% |
| Average Basic Shares Outstanding | 27.99% | 25.59% | 23.04% | 14.51% | 5.96% |
| Average Diluted Shares Outstanding | 27.99% | 25.59% | 23.04% | 14.51% | 5.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |